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Abstract
Background: Increased exposure to multitargeted kinase inhibitor sunitinib is associated with improved outcome,
emphasizing the importance of maintaining adequate dosing and drug levels. The currently approved schedule
(50 mg daily, four weeks on, two weeks off) precludes further dose-intensification. Recent data suggest that
sunitinib, although initially developed as an antiangiogenic agent, has direct antitumor activity.
Methods: In this study, we tested whether a chemotherapy-like schedule of pulsatile high dose sunitinib would
result in improved antitumor activity.
Results: In vitro, a single exposure to 20 μM sunitinib for 6-9 h resulted in complete inhibition of tumor cell growth
and cell death conveyed through activation of caspases and autophagy upregulation. Notably, repeated exposure
of tumor cells to pulses of high concentrations of sunitinib did not induce resistance. In vivo, once-weekly treatment
with high dose sunitinib of tumors growing on the chorioallantoic membrane (CAM) of the chicken embryo
significantly impaired tumor growth by 57 % compared to vehicle, outperforming the daily, standard scheduling.
Conclusions: These results prompted the initiation of a phase I clinical trial, where intermittent, high dose sunitinib is
being investigated in patients with advanced solid tumors (registration number and date: NCT02058901, 30 September
2013, respectively). The trial is actively recruiting patients and promising preliminary indications of antitumor activity
have been observed.
Keywords: Cancer, Sunitinib, Pulsatile, High dose, Alternative scheduling, CAM model, Apoptosis, Autophagy, Tumor
growth
Abbreviations: CAM, Chorioallantoic membrane of the chicken embryo; GIST, Gastrointestinal stromal tumor; LC3BI/
LC3BII, Microtubule-associated protein 1 light chain 3 I and II respectively; PDGFR, Platelet-derived growth factor
receptor; pNET, Pancreatic neuroendocrine tumor; RCC, Renal cell cancer; TKIs, Tyrosine kinase inhibitors;
VEGFR, Vascular endothelial growth factor receptor
Background
Competitive inhibition of aberrantly or mutationally acti-
vated protein kinases downregulates critical hallmarks of
cancer growth [1]. The introduction of tyrosine kinase in-
hibitors (TKIs) elicited remarkable therapeutic responses
in malignancies previously regarded as chemoresistant [2].
Despite these important strides, the field of TKIs faces sig-
nificant challenges, spanning from low response rates and
lack of selectivity to development of drug resistance [3]. A
crucial and challenging aspect in the clinical development
of TKIs is to determine a biologically active dose as well
as an optimal treatment schedule [4–6].
Sunitinib malate, (SUTENT; Pfizer, New York, NY), an
orally administered TKI, targets multiple receptors, in-
cluding the vascular endothelial growth factor receptor
(VEGFR) and platelet-derived growth factor receptor
(PDGFR). It has already been approved for the treatment
of advanced renal cell cancer (RCC), gastrointestinal* Correspondence: h.verheul@vumc.nl
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stromal tumors (GIST) and pancreatic neuroendocrine tu-
mors (pNET). The currently approved dose is 50 mg daily
for 4 weeks followed by a 2-week off period (4/2 schedule)
[4, 7, 8]. Various dose schedules have been assessed in
order to improve the efficacy of sunitinib. Daily and every-
other-day sunitinib administrations have been explored
which incorporated planned rest periods for both recovery
from toxicities and concerns of drug accumulation with
continuous dosing [9–11]. The relationship between suniti-
nib exposure, efficacy and safety has been evaluated in a
recent pharmacokinetic/pharmacodynamic (PK/PD) meta-
analysis. An exposure-response model demonstrated that
increased area under the curve levels of sunitinib resulted
in greater efficacy [12]. A recent study also demonstrated
that continuous daily dosing of sunitinib at the lower dose
of 37.5 mg has no benefit in efficacy and safety over the
standard 4/2 schedule [13]. In addition, although sunitinib
was developed as an antiangiogenic agent, the drug has
been shown to exert direct anti-tumor activity [14].
We recently demonstrated in patients that tumor con-
centrations of sunitinib are significantly higher compared
to their corresponding plasma concentrations (averaging
on 9.5 μM vs 0.3 μM, respectively). At this tumor concen-
tration, sunitinib was shown to inhibit proliferation of
various tumor cell lines in a dose-dependent manner, in-
cluding renal-, breast- and colon cancer cells. At high con-
centrations, complete blockade of proliferation and even
induction of tumor cell death was observed [15]. In this
study, we evaluated whether pulsatile exposure of cells to
high concentrations of sunitinib would induce cell death
and whether application of this scheduling would suppress
tumor growth in vivo.
Methods
Cell culture
The tumor cell lines 786-O, HT-29, MDA-MB-231, H1650
and A431 were cultured in Dulbecco's Modified Eagle's
Medium supplemented with 5 % FBS and maintained in a
humidified incubator containing 5 % CO2 at 37 °C. All cell
lines were authenticated by BaseClear, Leiden, Netherlands
by STR profiling (last date of authentication: June 2014).
Sunitinib was provided by Pfizer Global Pharmaceuticals
and was prepared as 20 mmol/l stock solution in dimethyl
sulfoxide (DMSO; Sigma-Aldrich) and stored at -20 °C.
Proliferation assays
Cytotoxicity of sunitinib was assessed by MTT assay as
described previously [15]. Briefly, cells were seeded in a
96-well plates and allowed to adhere for 24 h. A t = 0
measurement was carried out and cells were treated with
increased concentrations of sunitinib for the indicated
time intervals, followed by washing and maintaining in
DMEM medium (5 % FBS) for a total of 144 h. Next,
100 μl of MTT indicator dye (5 mg/ml) was added to
each well and the cells were incubated for 2 h at 37 °C.
After addition of 100 μl of DMSO solution to each well,
absorption was measured at 540 nm in a microplate
reader (Spectra Fluor Tecan, Salzburg, Austria). The
reading taken from the wells with cells cultured in con-
trol medium was used as 100 % viability value. Cell pro-
liferation was calculated using the following formula: %
of proliferation = [(144 h measurement of treated cells −
0 h measurement)/(144 h measurement of untreated
cells − 0 h measurement)] × 100 %. Subtracting the
measurement at the beginning of treatment (t = 0 meas-
urement) might result in negative value, representing
cell killing [14]. All experiments were performed in trip-
licate and repeated at least three times.
Intracellular measurement of sunitinib concentration
Utilizing the fluorescent properties of sunitinib, we pro-
duced initially a concentration dilution series of sunitinib
(0.01 to 40 μM) in medium only, that was measured in mi-
croplate reader (Spectra Fluor Tecan, Salzburg, Austria),
to build a concentration curve. Consecutively, 5,000 cells
per well were plated in 96-well plate, allowed to attach
overnight and exposed to the indicated sunitinib concen-
trations for 2 h. Medium was removed; cells were washed
with PBS and lysed in M-PER Mammalian Protein Extrac-
tion Reagent supplemented with protease and phosphatase
inhibitor cocktails (Pierce). Fluorescence was measured
again, the value of the blank well (containing cells but no
drug) was subtracted and after correlation with the con-
centration curve and correction for the number of cells,
the intracellular concentration of sunitinib was calculated.
Cell cycle and cell death analysis
Cells (150,000 cells /well) were seeded in 6-well plates.
After drug exposure as indicated, cells were trypsinized,
resuspended in medium collected from the matching sam-
ples and centrifuged at 1,200 rpm for 5 min. Cells were
stained with propidium iodide buffer (0/1 mg/ml, 0.1 %
RNAse) on ice in the dark. Subsequently, DNA content
was analyzed with FACSCalibur flowcytometer (Becton-
Dickinson, Immunocytometry Systems, San Jose, USA).
Extent of cell death was calculated by the subG1 peak.
Western blot analysis
After treatment as indicated, cells were lysed in Mamma-
lian Protein Extraction Reagent (M-PER) supplemented
with protease and phosphatase inhibitor cocktails (Pierce).
Micro BCA protein assay (Pierce) was used for determin-
ation of protein concentrations. Samples containing 50 μg
protein underwent electrophoresis on 8 % to 12 % SDS
polyacrylamide gels and were subsequently transferred to
PVDF membranes. Proteins were detected using the fol-
lowing antibodies: LC3B (#2775, Cell Signaling), SQTM1/
p62 (#8025, Cell Signaling) and β-actin (A5441; Sigma-
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Aldrich). After incubation with IRDye (infrared dye)-la-
beled secondary antibodies (LI-COR Biosciences), mem-
branes were scanned and analyzed with the Odyssey
Infrared Imaging System and accompanying software pro-
gram (LI-COR Biosciences; [16].
Determination of caspases 3/7 activity
786-O cells were plated in 96-well plate (5,000 cells/
well) and after overnight incubation, were treated with
the indicated concentrations for the indicated time inter-
vals. Activity of caspases 3/7 was determined using Apo-
ONE® Homogeneous Caspase-3/7 Assay, according to




Fertilized chicken White Leghorn eggs were incubated
in a hatching incubator with a relative air humidity of
65 % and a temperature of 37 °C. On post-fertilization
day 6, CAM surface was gently scratched and 5 x 106
HT29 cells in suspension with 50 % matrigel to a total
volume of 50 μl were grafted on the CAM. Sunitinib
40 mg/kg, a dose extrapolated from mice experiments,
was applied daily topically on the tumors on Embryonic
Developmental Day (EDD) 12-20 for the daily schedule
while sunitinib 120 mg/kg was applied topically on the
tumors only twice, on days 12 and 20 for the weekly
schedule. Dose for both schedules was calculated based
on the weight of the chicken embryo at the start of treat-
ment (EDD12). Tumor volume was calculated using an
external caliper and by the modified ellipsoid formula ½
x (length x width2). Plasma and tumors were collected
on EDD21. Tumors were weighed and cut, one half was
snap frozen and the other half was fixed in zinc-fixative
solution and embedded in paraffin.
Sunitinib measurements in CAM samples
Concentrations of sunitinib in the plasma and tumor
samples collected from the CAM was determined with
liquid chromatography—tandem mass spectrometry
(LC/MS-MS). Following weighing and overnight freeze-
drying of tumors, 200 μl of ice-cold 83 % acetonitrile
(ACN) was added for extraction and ultrasonicated for
10 min. After centrifugation, 50 μl of supernatant was
transferred for LC/MS-MS analysis as previously re-
ported for plasma and cell pellet homogenates [17].
Immunohistochemistry
Immunohistochemical staining was performed on 5 μm
thick paraffin sections of CAM tumors. Following depar-
affinization in xylene and rehydration through a graded
series of alcohol, endogenous peroxidase activity was
blocked by 20 min incubation in 0.3 % H2O2/PBS. Next,
antigen retrieval was performed in sodium citrate solution
(pH 6.0) using a pressure cooker. After blocking in 5 %
BSA/PBS for 30 min at room temperature (RT), the sam-
ples were incubated for 1 h at RT with the primary anti-
body diluted in 0.5 % BSA/PBS. Following primary
antibodies were used: CD31 (SZ31, Dianova) and Ki-67
(M7240; Dako; 1:50). Control slides were incubated with
0.5 % BSA/PBS. Next, the slides were incubated for
30 min at RT with the appropriate secondary biotinylated
antibody, followed by incubation with strep-ABC-HRP for
30 min at RT (1 μl avadin and 1 μl biotin in 500 μl PBS).
Finally, staining was visualized with 3,3-diamino-benzi-
dine-tetra hydrochloride (DAB), 0.3 mg/ml in 1 ml PBS
with 0.3 % H2O2. All slides were counterstained with
haematoxylin and mounted in Entellan (Merck) for mi-
croscopy. Three areas with the greatest amount of neovas-
cularization from each tumor section were selected and
the microvessels in these areas were counted under 40×
objective lens. Any brown-stained endothelial cell or endo-
thelial cell cluster that could be clearly separated from the
adjacent structures, with or without a vessel lumen, was
considered as a single, countable microvessel. The numbers
of microvessels in the three areas were averaged to give
mean microvascular density (MVD). Cancer proliferation
of CAM tumors was calculated as the ratio of the number
of nuclei stained for Ki67 to the total number of nuclei per
field and expressed as the percentage of Ki67-positive nu-
clei. Minimum of three pictures of each slide were taken at
10x magnification and quantification of positive DAB stain-
ing was done using Image J with colour deconvolution [18].
Statistical analysis
Results were subjected to statistical analysis using Graph-
Pad Prism v4.0 software. One-way ANOVA was followed
by Student's t-test, two-tailed and unpaired. Data are
expressed as means ± SEM or SD when appropriate.
Grubbs’ test was applied for exclusion of significant
outliers (p < 0.05 at significance level of a = 0.05). A p value
less than 0.05 was considered to be statistically significant.
Results
Pulsatile, high dose sunitinib inhibits tumor cell
proliferation
The 786-O renal cancer cell line was exposed to various
concentrations of sunitinib (5, 10 and 20 μM) for time
intervals ranging from 1 h to 1 week. In all cases, cell
viability was determined using the MTT assay, at the
end of the experiment after 7 days. We show that suniti-
nib in this pulsatile scheduling was a potent inhibitor of
cell proliferation in this scheduling. Exposure to 20 μM
of sunitinib for 1 to 3 h decreased cell proliferation by
50 % while incubation for 6 to 9 h resulted in complete
inhibition of the tumor cell viability (Fig. 1a). Exposure
concentration inversely correlated to exposure time, as
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similar inhibition of cell proliferation at lower concentra-
tions was reached only after prolonged exposure (continu-
ous incubation with 5 μM for 24 h, Fig. 1a). Similar results
were obtained with cell lines of different tumor types
(HT-29, H1650, MDA-MB231, A431), to exclude a cell
line specific effect (Fig. 1b). The cellular uptake of suniti-
nib was linear across the concentration range (Fig. 1c).
Pulsatile exposure to high dose sunitinib does not induce
resistance
We evaluated whether serial pulse application of high
doses would induce resistance to sunitinib. 786-O cells
were treated for 9 h with 20 μM of sunitinib after which
fresh medium was applied and cells were kept in culture
to allow regrowth. When these cultures reached con-
fluency after approximately two weeks, the same suniti-
nib schedule was applied. Sensitivity to sunitinib of these
repetitively treated cells (n = 4 times) was tested in com-
parison to untreated cells. Both cell types were equally
sensitive to sunitinib with IC50 values of 2 μM. (Fig. 1d, e).
Reduced cell viability by pulsatile sunitinib is mediated
by apoptosis
It has already been reported that, independent of angio-
genesis inhibition, sunitinib exerts direct antitumor ef-
fects [14]. As shown in Fig. 2a, the percentage of PI
positive cells, arrested at the subG1 cycle phase, in-
creased to 17 % after 9 h-exposure to 20 μM sunitinib in
786-O RCC cells. This percentage increased further to
61.5 % when these cells were subsequently washed and
incubated for 24 h in drug-free medium (Fig. 2a). To
further examine the contribution of apoptosis to the
mesured cell death, we determined the activation of exe-
cutioner caspase-3/7 after exposure of 786-O cells to 5
Fig. 1 Short exposure to high concentrations of sunitinib provokes tumor cell death, while serially treatment with this scheduling does not induce
resistance. a 786-O RCC cells were exposed to 5, 10 and 20 μM of sunitinib for the depicted time intervals, ranging from 1 – 144 h exposure.
Proliferation was studied at 144 h with MTT. b The indicated cancer cell lines were exposed to 20 μM of sunitinib for the various time intervals
(range 1- 144 h). Proliferation was studied at t = 144 h with MTT. Exposure to 20 μM of sunitinib for 9 h resulted in tumor cell death, independent of
cell line. c 786-O RCC cells were exposed to indicated sunitinib concentrations (range 0 – 20uM) for 6 h and intracellular accumulation of sunitinib was
calculated. d Sensitivity to sunitinib, determined with proliferation assay, of cells sequentially treated with 20 μM for 9 h (n = 4 times) was compared to
the sensitivity of untreated cells. e Photos depicting the regrowth of 786-O RCC cells after 9 h exposure to 20 μM of sunitinib. Control, untreated, D,
days after exposure. Error bars, SEM
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and 20 μM of sunitinib. We observed a concentration-
dependent increase in activation of caspase-3/7. Whereas
short or prolonged exposure to 5 μM of sunitinib failed to
activate caspase-3/7, exposure to 20 μM of sunitinib for
9 h resulted in a 12-fold increase in caspase-3/7 activa-
tion. Comparable induction of caspase activation was
observed only after longer (24 h) exposure (13- fold in-
crease, Fig. 2b).
Induction of autophagic flux after short exposure to high
concentrations of sunitinib
In cell lysates from 786-O cells exposed to increasing
concentrations of sunitinib (2, 10 and 20 μM) for 6 h,
protein levels of microtubule-associated protein 1 light
chain 3 I and II (LC3BI, LC3BII, respectively) and p62
were determined by western blotting to indicate the im-
pact of treatment on the autophagic flux. Six hours
Fig. 2 Pulsatile, high concentration of sunitinib leads to increase in the sub-G1 population, activation of caspase-3/7 and upregulation of autophagic
flux. a FACS analysis utilizing PI staining of 786-O RCC cells exposed to 20 μM of sunitinib after 1, 3, 9 h or 15 h after the 9-h exposure (9 > 24). Sunitinib
leads to proportional increase in sub-G1 population, indicative of cell death. b 786-O RCC cells were exposed for 3, 6, 9 and 24 h to 5 or
20 μM of sunitinib and activation of caspase-3/7 was measured. Data presented relative to control = 1. c, e LC3BI, LC3BII and p62 protein
levels in control and treated with the indicated concentrations of sunitinib cell lysates were analyzed by Western blotting. d, f Quantification of LC3BII/
LC3BI conversion ratio and p62 expression, respectively. For both figures, protein level was initially normalized towards the loading control, β-actin,
and then towards the corresponding control- untreated sample
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exposure to 2, 10 and 20 μM of sunitinib induced a
concentration-dependent increase in the conversion ra-
tio of LC3BII/LC3BI of 2.9, 5.3 and 15.2- fold, respect-
ively, compared to baseline expression of control cells
(Fig. 2c and d). A simultaneous decrease in the levels of
p62 was observed (20 %, 45 % and 64 % decrease com-
pared to control, after exposure to 2, 10 and 20 μM of
sunitinib, respectively, Fig. 2e and f). This increase in
the conversion ratio, in combination with the increased
degradation of p62, denotes a relevant increase in the
autophagic flux, possibly as a stress response to sunitinib
exposure.
Pulsatile, high dose sunitinib exhibits in vivo antitumor
activity and results in high intratumoral drug
concentration
The CAM model can efficiently support the growth of
tumor cells, thereby offering a reliable way to study pri-
mary tumor angiogenesis, anti-tumor therapies and
underlying molecular pathways in a biologically relevant
system that is both cost and time-effective. It can ad-
equately bridge the gap between monolayer cell cultures
and the intricate murine models, providing insights into
tumor growth and drug efficacy in an expedited way,
since tumors already form only 4 days after cell inocula-
tion. Simultaneously, high dose treatment with sunitinib
is not feasible in an in vivo murine tumor model. Previ-
ously maximally double or triple the established dose
(40 to 60 mg/kg) has been used as high dose while solu-
bility issues preclude further dose increase [19]. There-
fore, we investigated whether pulsatile, high dose
treatment with sunitinib would have antitumor activity
on HT29 xenograft tumors grown on the chorioallantoic
membrane of the chicken embryo (CAM). Limitation of
this in vivo model is the relatively short length of time
due to the grow of the embryo, which prohibits further
testing after 16 days of tumor inoculation [20].
Daily application of the commonly in vivo used sunitinib
dose (40 mg/kg) indeed induced a significant delay in
tumor growth (41 % decrease compared to vehicle treated
group, p < 0.05). However, this effect was even more prom-
inent in the treatment group of once weekly, high dose su-
nitinib of 120 mg/kg, that resulted in a 57 % decrease in
tumor growth compared to vehicle (p < 0.01) (Fig. 3a, b).
This inhibitory activity was confirmed on the tumor weight
after resection (mean tumor weight 0.17 mg (range: 0.08-
0.25 mg) vs 0.23 mg (range: 0.05-0.56 mg) vs 0.33 mg
(range: 0.11-0.87 mg) for the weekly vs daily treatment vs
vehicle group respectively; one way ANOVA p:0.018 and
Student’s t-test for the daily vs weekly: p = 0.02 (Fig. 3c).
This weekly, pulsatile high dose treatment led also to
higher plasma sunitinib concentrations compared to the
daily schedule (0.23 μM (range: 0.09-0.537 μM) vs 0.18 μM
(range: 0.09-0.25 μM), respectively, p = 0.0014), and higher
tumor concentrations (36 μM (range: 7.8-130 μM) for the
weekly vs 13.5 μM (range 7.0-37.4 μM) for the daily sched-
ule, p = 0.0002) (Fig. 3d, e). The observed growth inhibition
after pulsatile high dose scheduling seems to occur irre-
spective of angiogenesis inhibition, as denoted by the lack
of inhibitory effect on tumor microvessel density (MVD;
number of CD31+ vessels per 40x field: 24 (range: 13-39)
vs 27 (range: 16-53) vs 21 (range 17-24) for the vehicle vs
daily sunitinib vs weekly sunitinib group, respectively)
(Fig. 4a, b). Simultaneously, no differences in the Ki67 ex-
pression were found among the control, the daily and the
weekly schedule (Fig. 4a, c).
Discussion
The drug development of sunitinib is based on the con-
cept that inhibition of angiogenesis function induces
tumor cell death indirectly, through substrate deprivation.
Disassociating sunitinib from the concept of antiangiogen-
esis- only mediating function, we hypothesized that an al-
ternative dose scheduling could potentiate its efficacy
against a variety of cancer types. Our results show that
pulsatile high dose sunitinib can potently inhibit tumor
growth both in vitro and in vivo.
Short exposure to high concentrations of sunitinib in
vitro inhibited cancer cell proliferation as efficiently as
prolonged exposure to lower concentrations, without in-
ducing resistance. Apoptosis was involved in the cytoci-
dal process while induction of autophagy potentially
indicates a prosurvival reaction of the cells after expos-
ure to sunitinib. Consequently, intermittent application
of high doses of sunitinib on tumors growing on the
CAM in vivo model resulted in increased plasma and
intratumoral drug concentrations and significant inhib-
ition of tumor growth.
Optimizing TKI treatment regimens and dosing is an
important research field, aiming at improved antitumor
efficacy with acceptable toxicity and avoidance of induc-
tion of resistance. It is debatable whether the currently
approved TKI treatment scheduling is optimal in terms
of achieving maximum therapeutic responses. Challen-
ging the notion that prolonged protein kinase inhibition
is required to translate into efficacy, Shah et al. reported
that transient potent BCR-ABL inhibition by dasatinib
induces apoptotic pathways in chronic myeloid leukemia
cells [21]. Weekly, 10-fold higher than the currently ap-
proved, doses of erlotinib have been reported as salvage
therapy in patients with non-small cell lung cancer and
leptomeningeal metastases, with an acceptable toxicity
profile [22]. Interestingly, in 83 patients with metastatic
melanoma who received treatment with daily sorafenib
and PK-guided dose escalation, high area under the
curve (AUC) was the only parameter in the multivariate
analysis that correlated to efficacy [23]. Based on their
observation of markedly reduced sorafenib exposure at
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disease progression compared to baseline, Arrondeau et
al. proposed dose escalation aiming at restoration of
drug exposure and thereby treatment efficacy [24].
For imatinib, significantly lower plasma levels have been
correlated to a lack of response in patients with chronic
myeloid leukemia (CML) [25] and GIST [26]. Results from
the phase II 1046 axitinib trial [27], suggested that dose ti-
tration resulting in higher exposure is associated with im-
proved efficacy [28]. Chein et al., translating data from
mouse models where lapatinib in intermittent, high doses
demonstrated improved efficacy compared to the standard
continuous low-dose therapy, reported recently a phase I
trial investigating this schedule in patients with advanced
solid tumors [29]. Though an apparent exposure ceiling
seemed to preclude further dose escalation in the current
formulation, high-dose, intermittent lapatinib was well tol-
erated and resulted in significantly increased plasma con-
centrations. Additionally, a relationship between lapatinib
exposure and biologic activity was established; patients
with plasma concentrations approximating 10,000 ng/ml
Fig. 3 Pulsatile, high dose of sunitinib in vivo results in inhibition of tumor growth and significantly higher plasma and intratumoral sunitinib
concentrations compared to the standard, daily schedule. a Photos of HT29 tumors growing on the CAM representative of the three treatment
arms (vehicle, 40 mg/kg of sunitinib daily from EDD12 to EDD20 (designated as “daily) or 120 mg/kg twice per week, on EDD12 and EDD20
(designated as “weekly”). b Increase in tumor volume during treatment for the three treatment arms. Error bars, SEM. c Weight (in mg) of the
collected tumors, in each treatment arm. d, e Concentration of sunitinib in the plasma and the collected tumors per treatment arm. Error bars,
SD.*, p < 0.05, ** p < 0.01, NS: not significant
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presented marked responses, while all patients with low
lapatinib plasma concentrations exhibited progressive
disease [29].
For sunitinib it was recently found that continuous ad-
ministration of 37.5 mg sunitinib failed to exhibit super-
ior activity versus the approved four weeks on and two
weeks off treatment schedule of 50 mg sunitinib daily.
These findings not only further supported current clin-
ical practice, but also hinted that off drug periods do not
seem to compromise efficacy [12]. Since cumulative evi-
dence point to the relation of exposure to efficacy in this
class of agents, serial PK measurements are needed to iden-
tify patients with suboptimal exposure [30]. Employment of
our pulsatile high dose sunitinib treatment resulted in anti-
tumor activity without induction of resistance. This result
could have been anticipated, since in vitro resistance induc-
tion in cell lines requires prolonged exposure to these
agents [31]. Interestingly, it was recently demonstrated that
discontinuous scheduling of vemurafenib preempts the ap-
pearance of drug resistance, due to the regression of drug-
dependent, already established drug-resistant clones in the
interfering drug-free periods [32].
In our study, we report that sunitinib induces caspase-
dependent cell death. Previously, the antitumor activity of
sunitinib has been ascribed to activation of apoptosis in
tumor or endothelial cells and it has furthermore been
correlated to the baseline expression level of its target-
encoding genes [33]. In addition, exposure of cancer cells
to this scheduling of sunitinib upregulates autophagy, prob-
ably in the context of a pro-survival process and in line
with previous reports that autophagy acts as an adaptive
mechanism responding to, among others, antiangiogenic
treatment [34]. Whether the upregulation of autophagy is a
prosurvival reaction of cells or a cell death pathway that is
induced by this type of treatment scheduling remains an
open question, which requires further exploration. We did
not test separately the effect of the active metabolite of su-
nitinib, N-desethyl sunitinib, but it is known that it exhibits
similar potency compared to sunitinib in biochemical and
cellular assays (Sutent, Summary of Product Characteris-
tics, EMA).
Therefore, we would anticipate fully comparable re-
sults with the use of the metabolite.
The CAM model is able to efficiently support the
growth of tumor cells, thereby offering a reliable way to
study primary tumor formation and supportive angio-
genesis [20]. Pulsatile scheduling in our in vivo model
did not result into vessel pruning or tumor angiogenesis
inhibition, both reported to provoke intratumoral hypoxia,
an adaptive mechanism that has been implicated as a po-
tential resistance mechanism [35]. One obvious explan-
ation might be the short treatment window, a limiting
Fig. 4 Pulsatile, high dose sunitinib has no effect on tumor microvessel density (MVD) or on proliferation rate of cancer cells. a Representative
photos of (immunohistochemical) staining of tumors established on the CAM from HT-29 tumor cells, treated as indicated. Upper panel: CD31
staining; lower panel: Ki-67 staining b Quantification of microvessel density (MVD) using CD31 staining. Data are expressed as number of CD31
positive cells per field, x10 magnification. Scale bars, 100 μm c Quantification of tumor cell proliferation using Ki-67 staining. Data are expressed
as percentage of Ki-67 positive tumor cells to total tumor cells per field, 40x magnification. Scale bars, 50 μm.Error bars, SD
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factor in this model that may not allow perhaps sufficient
time for development and detection of such antiangio-
genic effects. Alternatively, inhibition of VEGF signaling
in this context might ultimately affect functions distinct
from angiogenesis, but implicated in tumorigenesis [36],
such as the autocrine and paracrine VEGF signaling in
tumor cells [36, 37]. However, we did not examine the po-
tential antiangiogenic activity of treatment on the CAM
membrane itself. Additionally, while sunitinib inhibited pri-
mary tumor growth, there was no effect on the cellular pro-
liferation rate, as indicated by the stable percentage of ki-67
positive cells in all treatment arms; this might be again at-
tributed to the limited treatment window but it could also
fall in line with the recent observation of prolonged stability
of tumor growth rate during sunitinib administration [38].
Our observed linear correlation between concentration and
cellular uptake indicate that increased plasma concentra-
tions might result in higher intratumoral concentrations.
Data concerning the blood TKI levels that are required to
achieve and maintain target inhibition are inadequate. For
sunitinib, plasma concentrations above 50 ng/mL are con-
sidered potentially active [4]. In non-clinical tissue speci-
mens, sunitinib concentration was found 13- to 308 fold
higher than in plasma [39]. In our in vivo model, the inter-
mittent application of a higher dose resulted in significantly
higher plasma concentrations compared to the daily appli-
cation of a lower dose, further leading to significantly
higher intratumoral concentrations. The results for the
daily schedule are directly comparable to previous reports
on plasma and tumor concentrations of sunitinib in pa-
tients where sunitinib intratumoral concentrations are 14
to 30-fold higher than plasma concentrations, consistent
with a large volume of distribution, reaching up to 50 μM
after standard daily treatment [15, 40].
The potent efficacy of sunitinib has been postulated to
result from simultaneous inhibition of individual target
receptors both in cancer cells and in the supporting
tumor vasculature [41]. Simultaneously, preclinical and
early clinical data raised the concern that antiangiogenic
treatment might potentiate the rate of metastases, acceler-
ate tumor growth and lead to a compensatory angiogenesis
boost; increase in cancer tissue hypoxia and pericyte abla-
tion are proposed to mechanistically facilitate metastasis
[19, 42, 43]. Contradictory data have been reported
whereby a transient improvement in tumor oxygenation
has been noted in tumor-bearing mice that receive treat-
ment with sunitinib [44], while prevention of hypoxia cor-
relates to metastasis inhibition [45]. This increase in tumor
perfusion after anti-angiogenic treatment in patients has
been correlated with improved prognosis [46], while select-
ive eradication of pericytes was correlated to enhanced effi-
cacy of antiangiogenic treatment [47]. Prospective clinical
trials attending to the complex nature of these questions
are lacking. However, recently Blagoev et al. addressed
these concerns utilizing data from the pivotal phase III trial
of sunitinib vs interferon-a in patients with RCC, that ul-
timately led to the approval of sunitinib as first line therapy
in this indication. The authors concluded that no evidence
indicated increased rate of tumor progression, following
treatment with sunitinib, while pointing out the discrepan-
cies with the preclinical data and commenting on the limi-
tations of murine models [48]. Additionally, analysis of
primary RCC tissues of patients preoperatively treated with
sunitinib suggested that an interval longer of 2 weeks off
drug is needed to observe increase in MVD that could fa-
cilitate tumor progression [43].
Our proposed pulsatile, high dose schedule might have
a number of potential implications with respect to the clin-
ical use of sunitinib. Since sunitinib presents with predict-
able, linear pharmacokinetics, one could assume that dose
increases might lead to proportional increases in drug ex-
posure, which in turn has been correlated to improved anti-
tumor efficiency [12]. To further investigate our initial
hypothesis and translating our preclinical data, we designed
a phase I trial, where high dose sunitinib is given in an
intermittent once weekly or once every two week schedule
(ClinicalTrials.gov Identifier: NCT02058901). The primary
aim of the study is the determination of Maximum Toler-
ated Dose (MTD) and the pharmacokinetic behavior of su-
nitinib, while an expansion cohort at the MTD level will
refine dose optimization and may offer a preliminary as-
sessment of the efficacy of this scheduling.
Conclusions
Identification of the optimal dose and scheduling of kinase
inhibitors, remains an open quest, ongoing even in the
postapproval setting. We here show for sunitinib, that an
increased exposure concentration requires a short exposure
time to result into potent antitumor activity, both in vitro
and in vivo. We have directly translated our findings in the
context of a phase I trial. Implications of this trial could be
the integration of this alternative scheduling of sunitinib in
daily practice and generalized application of the same dos-
ing strategy across small molecule development.
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